Value of functional imaging by PET in esophageal cancer

JNCCN Journal of the National Comprehensive Cancer Network

Volumn 13, Issue 2, 2015, Pages 239-247

  Schmidt, Thomas ^a   Lordick, Florian ^b   Herrmann, Ken ^c   Ott, Katja ^d  

^a UNIVERSITY OF HEIDELBERG   (Germany)

^b UNIVERSITY HOSPITAL LEIPZIG   (Germany)

^c UNIVERSITY HOSPITAL WÜRZBURG   (Germany)

^d Klinikum Rosenheim   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; FLUORODEOXYGLUCOSE F 18;

ADVANCED CANCER; CANCER ADJUVANT THERAPY; CANCER DIAGNOSIS; CANCER PROGNOSIS; CANCER REGRESSION; CANCER STAGING; CANCER SURVIVAL; ESOPHAGUS CANCER; HEALTH CARE QUALITY; HISTOPATHOLOGY; HUMAN; METABOLISM; METASTASIS; POSITRON EMISSION TOMOGRAPHY; PREOPERATIVE TREATMENT; REVIEW; COMPUTER ASSISTED TOMOGRAPHY; DIAGNOSTIC USE; ESOPHAGEAL NEOPLASMS; NEOPLASMS, MULTIPLE PRIMARY; PATHOLOGY; PROCEDURES; RADIOGRAPHY; SCINTISCANNING; TREATMENT OUTCOME;

ESOPHAGEAL NEOPLASMS; FLUORODEOXYGLUCOSE F18; HUMANS; NEOPLASM METASTASIS; NEOPLASM STAGING; NEOPLASMS, MULTIPLE PRIMARY; POSITRON-EMISSION TOMOGRAPHY; TOMOGRAPHY, X-RAY COMPUTED; TREATMENT OUTCOME;

EID: 84923517452     PISSN: 15401405     EISSN: 15401413     Source Type: Journal    
DOI: 10.6004/jnccn.2015.0030     Document Type: Review

References (85)

1. Ott K, Weber WA, Fink U, et al. Fluorodeoxyglucose-positron emission tomography in adenocarcinomas of the distal esophagus and cardia. World J Surg 2003;27:1035-1039
2. Cuellar SL, Carter BW, Macapinlac HA, et al. Clinical staging of patients with early esophageal adenocarcinoma: Does FDG-PET/CT have a role? J Thorac Oncol 2014;9:1202-1206
3. Sjoquist KM, Burmeister BH, Smithers BM, et al. Survival after neoadjuvant chemotherapy or chemoradiotherapy for resectable oesophageal carcinoma: An updated meta-analysis. Lancet Oncol 2011;12:681-692
4. van Hagen P, Hulshof MC, van Lanschot JJ, et al. Preoperative chemoradiotherapy for esophageal or junctional cancer. N Engl J Med 2012;366:2074-2084
5. Bedenne L, Michel P, Bouché O, et al. Chemoradiation followed by surgery compared with chemoradiation alone in squamous cancer of the esophagus: FFCD 9102. J Clin Oncol 2007;25:1160-1168
6. Stahl M, Walz MK, Stuschke M, et al. Phase III comparison of preoperative chemotherapy compared with chemoradiotherapy in patients with locally advanced adenocarcinoma of the esophagogastric junction. J Clin Oncol 2009;27:851-856
7. Pfau PR, Perlman SB, Stanko P, et al. The role and clinical value of EUS in a multimodality esophageal carcinoma staging program with CT and positron emission tomography. Gastrointest Endosc 2007;65:377-384
8. Thosani N, Singh H, Kapadia A, et al. Diagnostic accuracy of EUS in differentiating mucosal versus submucosal invasion of superficial esophageal cancers: A systematic review and meta-analysis. Gastrointest Endosc 2012;75:242-253
9. Pech O, May A, Manner H, et al. Long-term efficacy and safety of endoscopic resection for patients with mucosal adenocarcinoma of the esophagus. Gastroenterology 2014;146:652-660
10. Moon SH, Kim HS, Hyun SH, et al. Prediction of occult lymph node metastasis by metabolic parameters in patients with clinically No esophageal squamous cell carcinoma. J Nucl Med 2014;55:743-748
11. Karashima R,Watanabe M, Imamura Y, et al. Advantages of FDG-PET/CT over CT alone in the preoperative assessment of lymph node metastasis in patients with esophageal cancer [published online ahead of print June 28, 2014]. Surg Today, in press
12. Foley KG, Lewis WG, Fielding P, et al. N-staging of oesophageal and junctional carcinoma: Is there still a role for EUS in patients staged N0 at PET/CT? Clin Radiol 2014;69:959-964
13. Blank S, Lordick F, Dobritz M, et al. A reliable risk score for stage IV esophagogastric cancer. Eur J Surg Oncol 2013;39:823-830
14. Stahl M, Mariette C, Haustermans K, et al. Oesophageal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2013;24(Suppl 6):vi51-56
15. Gillies RS, Middleton MR, Maynard ND, et al. Additional benefit of (1)(8)F-fluorodeoxyglucose integrated positron emission tomography/ computed tomography in the staging of oesophageal cancer. Eur Radiol 2011;21:274-280
16. Meyers BF, Downey RJ, Decker PA, et al. The utility of positron emission tomography in staging of potentially operable carcinoma of the thoracic esophagus: Results of the American College of Surgeons Oncology Group Z0060 trial. J Thorac Cardiovasc Surg 2007;133:738-745
17. Noble F, Bailey D, Tung K, Byrne JP. Impact of integrated PET/CT in the staging of oesophageal cancer: A UK population-based cohort study. Clin Radiol 2009;64:699-705
18. Pifarré-Montaner P, Fernández-León A, de Juan R, et al. Impact of (18) F-FDG PET/CT on the therapeutic management in the initial staging of the esophageal cancer [in Spanish]. Rev Esp Med Nucl 2009;28:101-105
19. Purandare NC, Pramesh CS, Karimundackal G, et al. Incremental value of 18F-FDG PET/CT in therapeutic decision-making of potentially curable esophageal adenocarcinoma. Nucl Med Commun 2014;35:864-869
20. Salahudeen HM, Balan A, Naik K, et al. Impact of the introduction of integrated PET-CT into the preoperative staging pathway of patients with potentially operable oesophageal carcinoma. Clin Radiol 2008;63:765-773
21. Walker AJ, Spier BJ, Perlman SB, et al. Integrated PET/CT fusion imaging and endoscopic ultrasound in the pre-operative staging and evaluation of esophageal cancer. Mol Imaging Biol 2011;13:166-171
22. You JJ, Wong RK, Darling G, et al. Clinical utility of 18F-fluorodeoxyglucose positron emission tomography/computed tomography in the staging of patients with potentially resectable esophageal cancer. J Thorac Oncol 2013;8:1563-1569
23. Miyazaki T, Sohda M, Higuchi T, et al. Effectiveness of FDG-PET in screening of synchronous cancer of other organs in patients with esophageal cancer. Anticancer Res 2014;34:283-287
24. Blom RL, Schreurs WM, Belgers HJ, et al. The value of post-neoadjuvant therapy PET-CT in the detection of interval metastases in esophageal carcinoma. Eur J Surg Oncol 2011;37:774-778
25. Bruzzi JF, Swisher SG, Truong MT, et al. Detection of interval distant metastases: Clinical utility of integrated CT-PET imaging in patients with esophageal carcinoma after neoadjuvant therapy. Cancer 2007;109:125-134
26. Stiekema J, Vermeulen D, Vegt E, et al. Detecting interval metastases and response assessment using 18F-FDG PET/CT after neoadjuvant chemoradiotherapy for esophageal cancer. Clin Nucl Med 2014;39:862-867
27. Schmidt T, Sicic L, Blank S, et al. Prognostic value of histopathological regression in 850 neoadjuvantly treated oesophagogastric adenocarcinomas. Br J Cancer 2014;110:1712-1720
28. Ott K, Schmidt T, Lordick F, Herrmann K. Importance of PET in surgery of esophageal cancer [in German]. Chirurg 2014;85:505-512
29. Zhu W, Xing L, Yue J, et al. Prognostic significance of SUV on PET/CT in patients with localised oesophagogastric junction cancer receiving neoadjuvant chemotherapy/chemoradiation: A systematic review and meta-analysis. Br J Radiol 2012;85:e694-701
30. Japanese Gastric Cancer Association. Japanese classification of gastric carcinoma-2nd English edition-response assessment of chemotherapy and radiotherapy for gastric carcinoma: Clinical criteria. Gastric Cancer 2001;4:1-8
31. Eisenhauer EA, Therasse P, Bogaerts J, et al. New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1). Eur J Cancer 2009;45:228-247
32. Heger U, Blank S, Wiecha C, et al. Is preoperative chemotherapy followed by surgery the appropriate treatment for signet ring cell containing adenocarcinomas of the esophagogastric junction and stomach? Ann Surg Oncol 2014;21:1739-1748
33. Karamitopoulou E, Thies S, Zlobec I, et al. Assessment of tumor regression of esophageal adenocarcinomas after neoadjuvant chemotherapy: Comparison of 2 commonly used scoring approaches. Am J Surg Pathol 2014;38:1551-1556
34. Lordick F, Ott K, Krause BJ, et al. PET to assess early metabolic response and to guide treatment of adenocarcinoma of the oesophagogastric junction: The MUNICON phase II trial. Lancet Oncol 2007;8:797-805
35. zum Büschenfelde CM, Herrmann K, Schuster T, et al. (18)F-FDG PETguided salvage neoadjuvant radiochemotherapy of adenocarcinoma of the esophagogastric junction: the MUNICON II trial. J Nucl Med 2011;52:1189-1196.
36. Ott K, Sendler A, Becker K, et al. Neoadjuvant chemotherapy with cisplatin, 5-FU, and leucovorin (PLF) in locally advanced gastric cancer: A prospective phase II study. Gastric Cancer 2003;6:159-167
37. Heger U, Bader F, Lordick F, et al. Interim endoscopy results during neoadjuvant therapy for gastric cancer correlate with histopathological response and prognosis. Gastric Cancer 2014;17:478-488
38. Blank S, Lordick F, Bader F, et al. Post-therapeutic response evaluation by a combination of endoscopy and CT scan in esophagogastric adenocarcinoma after chemotherapy: better than its reputation [published online ahead of print April 11, 2014]. Gastric Cancer, in press
39. Mandard AM, Dalibard F, Mandard JC, et al. Pathologic assessment of tumor regression after preoperative chemoradiotherapy of esophageal carcinoma. Clinicopathologic correlations. Cancer 1994;73:2680-2686
40. Langer R, Ott K, Feith M, et al. Prognostic significance of histopathological tumor regression after neoadjuvant chemotherapy in esophageal adenocarcinomas. Mod Pathol 2009;22:1555-1563
41. Shapiro J, van Hagen P, Lingsma HF, et al. Prolonged time to surgery after neoadjuvant chemoradiotherapy increases histopathological response without affecting survival in patients with esophageal or junctional cancer. Ann Surg 2014;260:807-814
42. Slotta-Huspenina J, Wolff C, Drecoll E, et al. A specific expression profile of heat-shock proteins and glucose-regulated proteins is associated with response to neoadjuvant chemotherapy in oesophageal adenocarcinomas. Br J Cancer 2013;109:370-378
43. Cunningham D, Allum WH, Stenning SP, et al. Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. N Engl J Med 2006;355:11-20
44. Ychou M, Boige V, Pignon JP, et al. Perioperative chemotherapy compared with surgery alone for resectable gastroesophageal adenocarcinoma: An FNCLCC and FFCD multicenter phase III trial. J Clin Oncol 2011;29:1715-1721
45. Lutz MP, Zalcberg JR, Ducreux M, et al. Highlights of the EORTC St. Gallen International Expert Consensus on the primary therapy of gastric, gastroesophageal and oesophageal cancer - differential treatment strategies for subtypes of early gastroesophageal cancer. Eur J Cancer 2012;48:2941-2953
46. Blank S, Stange A, Sisic L, et al. Preoperative therapy of esophagogastric cancer: The problem of nonresponding patients. Langenbecks Arch Surg 2013;398:211-220
47. Jouve J, Miche P, Mariette C, et al. Outcome of the nonrandomized patients in the FFCD 9102 trial: Chemoradiation followed by surgery compared with chemoradiation alone in squamous cancer of the esophagus [abstract]. J Clin Oncol 2008;26(Suppl):Abstract 4555
48. Castoro C, Scarpa M, Cagol M, et al. Complete clinical response after neoadjuvant chemoradiotherapy for squamous cell cancer of the thoracic oesophagus: Is surgery always necessary? J Gastrointest Surg 2013;17:1375-1381
49. Wieder HA, Brücher BL, Zimmermann F, et al. Time course of tumor metabolic activity during chemoradiotherapy of esophageal squamous cell carcinoma and response to treatment. J Clin Oncol 2004;22:900-908
50. Swisher SG, Erasmus J, Maish M, et al. 2-Fluoro-2-deoxy-D-glucose positron emission tomography imaging is predictive of pathologic response and survival after preoperative chemoradiation in patients with esophageal carcinoma. Cancer 2004;101:1776-1785
51. Hong D, Lunagomez S, Kim EE, et al. Value of baseline positron emission tomography for predicting overall survival in patient with nonmetastatic esophageal or gastroesophageal junction carcinoma. Cancer 2005;104:1620-1626
52. Ott K, Weber WA, Lordick F, et al. Metabolic imaging predicts response, survival, and recurrence in adenocarcinomas of the esophagogastric junction. J Clin Oncol 2006;24:4692-4698
53. Levine EA, Farmer MR, Clark P, et al. Predictive value of 18-fluorodeoxy- glucose-positron emission tomography (18F-FDG-PET) in the identification of responders to chemoradiation therapy for the treatment of locally advanced esophageal cancer. Ann Surg 2006;243:472-478
54. Rizk NP, Tang L, Adusumilli PS, et al. Predictive value of initial PETSUVmax in patients with locally advanced esophageal and gastroesophageal junction adenocarcinoma. J Thorac Oncol 2009;4:875-879
55. Palie O, Michel P, Ménard JF, et al. The predictive value of treatment response using FDG PET performed on day 21 of chemoradiotherapy in patients with oesophageal squamous cell carcinoma. A prospective, multicentre study (RTEP3). Eur J Nucl Med Mol Imaging 2013;40:1345-1355
56. Suzuki A, Xiao L, Hayashi Y, et al. Prognostic significance of baseline positron emission tomography and importance of clinical complete response in patients with esophageal or gastroesophageal junction cancer treated with definitive chemoradiotherapy. Cancer 2011;117:4823-4833
57. Jayachandran P, Pai RK, Quon A, et al. Postchemoradiotherapy positron emission tomography predicts pathologic response and survival in patients with esophageal cancer. Int J Radiat Oncol Biol Phys 2012;84:471-477
58. Piessen G, Petyt G, Duhamel A, et al. Ineffectiveness of 18F-fluorodeoxyglucose positron emission tomography in the evaluation of tumor response after completion of neoadjuvant chemoradiation in esophageal cancer. Ann Surg 2013;258:66-76
59. Schollaert P, Crott R, Bertrand C, et al. A systematic review of the predictive value of (18)FDG-PET in esophageal and esophagogastric junction cancer after neoadjuvant chemoradiation on the survival outcome stratification. J Gastrointest Surg 2014;18:894-905
60. Kwee RM. Prediction of tumor response to neoadjuvant therapy in patients with esophageal cancer with use of 18F FDG PET: A systematic review. Radiology 2010;254:707-717
61. Javeri H, Xiao L, Rohren E, et al. The higher the decrease in the standardized uptake value of positron emission tomography after chemoradiation, the better the survival of patients with gastroesophageal adenocarcinoma. Cancer 2009;115:5184-5192
62. Kauppi JT, Oksala N, Salo JA, et al. Locally advanced esophageal adenocarcinoma: Response to neoadjuvant chemotherapy and survival predicted by ([18F])FDG-PET/CT. Acta Oncol 2012;51:636-644
63. Vallböhmer D, Hölscher AH, Dietlein M, et al. [18F]-Fluorodeoxyglucosepositron emission tomography for the assessment of histopathologic response and prognosis after completion of neoadjuvant chemoradiation in esophageal cancer. Ann Surg 2009;250:888-894
64. Schmidt M, Bollschweiler E, Dietlein M, et al. Mean and maximum standardized uptake values in [18F]FDG-PET for assessment of histopathological response in oesophageal squamous cell carcinoma or adenocarcinoma after radiochemotherapy. Eur J Nucl Med Mol Imaging 2009;36:735-744
65. Abdelsalam M, Bazarbashi S, Abouzied M, et al. Whole body 18F-FDG PET predicts progression free and overall survival in squamous cell carcinoma of the esophagus: Results of a prospective trial. Hematol Oncol Stem Cell Ther 2010;3:179-184
66. Smith JW, Moreira J, Abood G, et al. The influence of (18) flourodeoxyglucose positron emission tomography on the management of gastroesophageal junction carcinoma. Am J Surg 2009;197:308-312
67. Konski AA, Cheng JD, Goldberg M, et al. Correlation of molecular response as measured by 18-FDG positron emission tomography with outcome after chemoradiotherapy in patients with esophageal carcinoma. Int J Radiat Oncol Biol Phys 2007;69:358-363
68. Molena D, Sun HH, Badr AS, et al. Clinical tools do not predict pathological complete response in patients with esophageal squamous cell cancer treated with definitive chemoradiotherapy. Dis Esophagus 2014;27:355-359
69. Cerfolio RJ, Bryant AS, Talati AA, et al. Change in maximum standardized uptake value on repeat positron emission tomography after chemoradiotherapy in patients with esophageal cancer identifies complete responders. J Thorac Cardiovasc Surg 2009;137:605-609
70. Swisher SG, Maish M, Erasmus JJ, et al. Utility of PET, CT, and EUS to identify pathologic responders in esophageal cancer. Ann Thorac Surg 2004;78:1152-1160
71. Yen TJ, Chung CS, Wu YW, et al. Comparative study between endoscopic ultrasonography and positron emission tomography-computed tomography in staging patients with esophageal squamous cell carcinoma. Dis Esophagus 2012;25:40-47
72. Port JL, Lee PC, Korst RJ, et al. Positron emission tomographic scanning predicts survival after induction chemotherapy for esophageal carcinoma. Ann Thorac Surg 2007;84:393-400; discussion 400
73. Kim MK, Ryu JS, Kim SB, et al. Value of complete metabolic response by (18)F-fluorodeoxyglucose-positron emission tomography in oesophageal cancer for prediction of pathologic response and survival after preoperative chemoradiotherapy. Eur J Cancer 2007;43:1385-1391
74. Erasmus JJ, Munden RF, Truong MT, et al. Preoperative chemo-radiationinduced ulceration in patients with esophageal cancer: A confounding factor in tumor response assessment in integrated computed tomographicpositron emission tomographic imaging. J Thorac Oncol 2006;1:478-486
75. Moehler M, Baltin CT, Ebert M, et al. International comparison of the German evidence-based S3-guidelines on the diagnosis and multimodal treatment of early and locally advanced gastric cancer, including adenocarcinoma of the lower esophagus [published online ahead of print September 7, 2014}. Gastric Cancer, in press
76. Moehler M, Al-Batran SE, Andus T, et al. German S3-guideline "Diagnosis and treatment of esophagogastric cancer" [in German]. Z Gastroenterol 2011;49:461-531
77. Ajani JA, D'Amico TA, Almhanna K, et al. NCCN Clinical Practice Guidelines in Oncology for Esophageal and Esophagogastric Junction Cancers. Version 1, 2015. Available at: NCCN.org. Accessed January 12, 2015
78. van Heijl M, Omloo JM, van Berge Henegouwen MI, et al. Fluorodeoxyglucose positron emission tomography for evaluating early response during neoadjuvant chemoradiotherapy in patients with potentially curable esophageal cancer. Ann Surg 2011;253:56-63
79. Weber WA, Ott K, Becker K, et al. Prediction of response to preoperative chemotherapy in adenocarcinomas of the esophagogastric junction by metabolic imaging. J Clin Oncol 2001;19:3058-3065
80. Ott K, Fink U, Becker K, et al. Prediction of response to preoperative chemotherapy in gastric carcinoma by metabolic imaging: Results of a prospective trial. J Clin Oncol 2003;21:4604-4610
81. Ilson DH, Minsky BD, Ku GY, et al. Phase 2 trial of induction and concurrent chemoradiotherapy with weekly irinotecan and cisplatin followed by surgery for esophageal cancer. Cancer 2012;118:2820-2827
82. Wieder HA, Ott K, Lordick F, et al. Prediction of tumor response by FDGPET: Comparison of the accuracy of single and sequential studies in patients with adenocarcinomas of the esophagogastric junction. Eur J Nucl Med Mol Imaging 2007;34:1925-1932
83. Westerterp M, Omloo JM, Sloof GW, et al. Monitoring of response to pre-operative chemoradiation in combination with hyperthermia in oesophageal cancer by FDG-PET. Int J Hyperthermia 2006;22:149-160
84. Ott K, Herrmann K, Lordick F, et al. Early metabolic response evaluation by fluorine-18 fluorodeoxyglucose positron emission tomography allows in vivo testing of chemosensitivity in gastric cancer: Long-term results of a prospective study. Clin Cancer Res 2008;14:2012-2018
85. Malik V, Lucey JA, Duffy GJ, et al. Early repeated 18F-FDG PET scans during neoadjuvant chemoradiation fail to predict histopathologic response or survival benefit in adenocarcinoma of the esophagus. J Nucl Med 2010;51:1863-1869.